LivaNova Announces 150th Bipolar Depression Patient Randomized In RECOVER Clinical Study
Portfolio Pulse from Benzinga Newsdesk
LivaNova announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study, assessing the safety and effectiveness of VNS Therapy System. The study aims to offer another treatment option for patients with treatment-resistant depression.
June 13, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LivaNova's RECOVER clinical study reaches a milestone with 150 bipolar patients randomized, potentially leading to a new treatment option for treatment-resistant depression.
LivaNova's RECOVER study has reached a significant milestone with 150 bipolar patients randomized. This progress indicates that the study is on track and could potentially lead to a new treatment option for patients with treatment-resistant depression. If the study results are positive, it could boost LivaNova's reputation and market position in the medical technology sector, leading to a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100